Peptides

What are peptides? One word, three completely different markets

By the US Health Digest editorial team · July 28, 2026

"Peptide" is a chemistry word — a short chain of amino acids — and it tells you almost nothing about whether a product is tested, legal, or safe. The same six letters cover three markets with no common evidence standard. The first is prescription medicine: insulin, the GLP-1 drugs, and bremelanotide are all peptides — semaglutide produced 14.9% mean weight loss at 68 weeks versus 2.4% on placebo in the 1,961-patient STEP 1 trial. The second is the supplement aisle, where collagen peptides are sold as food and the latest meta-analysis of 23 randomized trials concluded there is "currently no clinical evidence to support the use of collagen supplements to prevent or treat skin aging". The third is a gray market of vials — BPC-157, TB-500, KPV, MOTS-c — labeled "research purposes only," a disclaimer FDA has told sellers does not change what the products legally are. On July 23, 2026 an FDA advisory committee voted 8–6 with one abstention to recommend letting compounding pharmacies use BPC-157 — a non-binding vote, over the objections of FDA's own scientists, that the agency has not acted on.

The chemistry is simple. The market is not.

A peptide is a chain of amino acids joined by peptide bonds. Longer chains are called proteins; the cutoff is convention, not biology. In the body, peptides mostly act as signals — hormones and messengers that tell cells what to do.

That is the entire definition. It says nothing about evidence, manufacturing, or legality — which is why the word is so useful to marketers. As STAT and Undark put it in a February 2026 investigation, "Insulin, for example, is an FDA-approved peptide, as are GLP-1s, the popular weight loss drugs" — the same chemical class as the substances shipped from forum-recommended websites.

So the useful question is never "is this a peptide?" It is which of the three markets does this product belong to?

The three markets at a glance

Market one: peptides that are approved drugs

Some of the most consequential medicines of the last century are peptides. Insulin shows how blurry the labels are: in a final rule announced in February 2020, FDA set up the March 2020 transition of insulin products from approved drug applications to licensed biological products. The molecule did not change; the legal category did.

The GLP-1 receptor agonists now dominating obesity medicine are peptides too, and their approval rests on large randomized trials: STEP 1 found 14.9% mean weight loss with semaglutide at 68 weeks against 2.4% with placebo across 1,961 adults, and SURMOUNT-1 reported reductions of up to 20.9% at 72 weeks with tirzepatide. What those averages mean for individuals is the subject of semaglutide results in women and our GLP-1 statistics roundup.

Not every approved peptide is about weight. Bremelanotide, marketed as Vyleesi, is an injected melanocortin-receptor peptide approved in June 2019 for "premenopausal women with acquired, generalized hypoactive sexual desire disorder" — a narrow indication with a specific label, which is what an approval actually is.

What defines this market is not chemistry but paperwork: a sponsor submitted trial data, FDA reviewed it, and the label states who the drug is for, at what dose, and what harms appeared. Our summary of GLP-1 side effects in the trials rests on that evidence, which does not exist for markets two and three.

Market two: the supplement aisle

Collagen peptides — hydrolysed collagen, usually bovine, porcine, or marine — are sold as food or dietary supplements. That is a different legal universe: FDA does not approve supplements before sale, manufacturers substantiate their own claims, and FDA's consumer guidance is explicit that its role here is largely post-market.

The human literature is real but contested, and the contest is instructive. A 2023 meta-analysis in Nutrients pooled 26 randomized trials with 1,721 participants and found significant improvements in skin hydration and elasticity versus placebo, while noting it "identified several biases in the included RCTs." A 2025 meta-analysis in the American Journal of Medicine asked a sharper question: across 23 randomized trials with 1,474 participants the pooled result again looked positive — but by subgroup, "studies not receiving funding from pharmaceutical companies revealed no effect of collagen supplements for improving skin hydration, elasticity, and wrinkles, while those receiving funding from pharmaceutical companies did show significant effects." High-quality studies showed no effect in any category. The conclusion: "There is currently no clinical evidence to support the use of collagen supplements to prevent or treat skin aging."

Two honest readings follow. Collagen peptides are food-grade protein fragments with a long dietary history, so the safety questions are modest. But the efficacy signal tracks who paid for the study — a reason for caution about advertising claims, not proof of no effect. Positive trials keep appearing: a 100-participant placebo-controlled study in 2024 reported better wrinkle and elasticity measures at 12 weeks, with manufacturer-employed authors.

The Federal Trade Commission's standard applies to every claim in this aisle: advertisers need "competent and reliable scientific evidence," and the FTC's health products compliance guidance states that "anecdotal evidence about the individual experiences of consumers, including surveys of consumer experiences, are never sufficient to substantiate claims about the effects of a health product," and that animal and in vitro studies, "without confirmation by human RCTs," are not sufficient either.

Market three: "research use only"

The third market sells injectable peptides never approved for anything, through websites that label the vials for laboratory use. BPC-157 is the emblem of the category: isolated from human gastric juice in Zagreb, with the earliest PubMed entry dating to 1992, and nearly all subsequent research in rodents.

FDA's position on that disclaimer is not ambiguous. In warning letters issued December 10, 2024 to five online sellers — including firms trading as Prime Peptides, Summit Research Peptides, and Xcel Research — it wrote that "Despite statements on your product labeling marketing your products for 'research purposes only' and 'not for human consumption or clinical use,' evidence obtained from your website establishes that your products are intended to be drugs for human use." The letters are catalogued on FDA's health fraud warning letter index. What makes a product a drug, in FDA's reading, is intended use — shown by the site's claims, not the label's disclaimer.

The purity question is larger still. "You don't even know what you're buying inside that bottle," Matthew Fedoruk, chief science officer of the U.S. Anti-Doping Agency, told Undark. "It could be a peptide. It could be a steroid. It could be something just like water."

FDA has written down its own concerns. Its catalogue of bulk substances that "may present significant safety risks" records that compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities," and that FDA "has not identified any human exposure data" for KPV or TB-500. Read the page carefully, though: those peptide entries now sit in its second table, "bulk drug substances nominated but withdrawn," which FDA describes as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators." A withdrawn nomination is neither an FDA prohibition nor an FDA clearance — it means whoever asked for the substance to be listed stopped asking, and FDA's stated safety concerns are still printed beside it. The active category 2 table is a separate list, and ipamorelin acetate, GHRP-2, GHRP-6 and kisspeptin-10 are still on it.

What "compounding" means, and why 503A and 503B are not the same thing

Compounding is a pharmacy combining or altering ingredients for a patient whose needs an approved product cannot meet — a dye allergy, an inability to swallow tablets. It is legal and long-standing. It is not approval. FDA's explainer is blunt: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."

Two sections of federal law create two kinds of compounder, and that distinction is doing a lot of work in the current fight.

Both lists govern bulk drug substances — raw active ingredient powder — and each is built through its own legal test, so a substance on one is not thereby on the other. FDA describes the 503A list as compiled through "notice-and-comment rulemaking," with the Pharmacy Compounding Advisory Committee consulted along the way.

The July 2026 moment: one door opening, another closing

On July 23 and 24, 2026, the Pharmacy Compounding Advisory Committee met to consider seven peptides for the 503A bulks list: BPC-157, KPV, TB-500 and MOTs-C on day one; Emideltide (DSIP), Semax and Epitalon on day two.

It voted 8–6, with one abstention, to recommend BPC-157 — a peptide "touted online as a way to promote gut and tissue healing." It recommended five more and rejected only Emideltide, by a tally TIME reported as 6 to 7.

It did so over the assessment of FDA's own scientists, who concluded the criteria weighed against adding BPC-157 and KPV. For BPC-157, TIME reported, the only effectiveness trial staff could find was a meeting abstract on 46 people, given the peptide as an enema, not an injection. For KPV, "None of the studies that staff found in its evaluation of the peptide were in humans." Dr. Elizabeth Rebello, of the University of Texas MD Anderson Cancer Center, said she was "concerned that we're responding to a market-induced demand rather than a decision based in solid science." Dr. Peter Lurie — a former FDA associate commissioner who now heads the advocacy group Center for Science in the Public Interest — warned that "Allowing peptides to be compounded removes incentives to go through FDA's rigorous drug approval process." Dissenters worried, ABC News reported, that listing would "create a false impression that it has been evaluated with the same rigorous standards as an FDA-approved drug."

Nothing has changed yet. FDA states that "Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so." Adding a substance to the 503A list requires rulemaking; as of this writing the vote is a recommendation and nothing more. We go through the BPC-157 evidence and its legal status in detail in what the BPC-157 human evidence actually shows.

Meanwhile, on the other list

In the same season, FDA moved the opposite way on the peptides with the most evidence behind them. A Federal Register notice published May 1, 2026 (91 FR 23431) sought comment on "FDA's proposal not to include semaglutide, tirzepatide, or liraglutide" on the 503B clinical-need list. A June 26 notice extended the comment period by 30 days, to July 30, 2026.

These are two lists governing two kinds of pharmacy under different statutory tests, so the pair is not a contradiction. But the timing is worth stating plainly: FDA is weighing closing the outsourcing-facility route for peptides backed by the large randomized trials above, in the same months its advisory committee voted to open the pharmacy route to peptides backed, in one case, by no human studies. FDA's stated reason on the GLP-1 side is the safety record: as of May 31, 2026 it had received 990 adverse-event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, and in March 2026 it warned 30 telehealth companies over marketing implying compounded products were equivalent to approved ones. We track that fight in the compounded GLP-1 endgame and compare routes in compounded versus branded GLP-1s.

Working out which market a product belongs to

Four checks will place almost any peptide product you encounter.

1. Does it have an FDA label? Search the active ingredient on DailyMed. Prescribing information with an indication, dose, and adverse-reaction table means market one.
2. Is it eaten or injected? A powder you stir into coffee, sold beside protein and creatine, is market two. An injectable sold without a prescription is not.
3. Read the disclaimer. "Research purposes only" or "not for human consumption" places a product in market three — and, per FDA's warning letters, does not make selling it for human use lawful.
4. Check who is between you and the vial. A pharmacy filling a prescription is a different transaction from a website that ships on a credit card. If a clinic prescribes a compounded peptide, ask which pharmacy fills it.

A hard case: "compounded semaglutide" from a telehealth service. That is market one chemistry through a compounding route — the molecule has trial evidence, but the product has not been reviewed by FDA for safety, effectiveness or quality. Our GLP-1 FAQ covers what to ask; the oral GLP-1 pill guide covers approved non-injectable options.

Questions to ask before you buy or are prescribed a peptide

• Is there an FDA-approved product containing this substance, and if so, why am I being offered a different version?
• Has it been tested in humans — how many, how long, published where? At the July 2026 hearing the answer was sometimes that no human studies were found.
• Who funded the studies I am being shown? The 2025 collagen meta-analysis shows why that changes the answer.
• Where was it made, and can I see a certificate of analysis for the lot?
• If compounded: which pharmacy, 503A or 503B, and is the bulk substance on the corresponding list?
• What adverse effects are documented, and who do I call if I have one?
• Is the seller making disease claims while labeling the product "not for human consumption"? That is the conduct FDA cited in its December 2024 warning letters.
• Does my prescriber have a financial interest in what they recommend?

The bottom line

The peptide boom is not one phenomenon. It is a pharmacological advance in market one, a modest and disputed consumer-goods story in market two, and an unregulated import trade in market three — bound together by nothing but a word from a biochemistry textbook. The questions before FDA will decide whether the boundary between markets one and three stays legible. Until they are settled, the buyer has to draw it: label, route, disclaimer, evidence.